These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 3258473)

  • 1. Myelopoietic effect of bone marrow fibroblasts cultured from patients with myelofibrosis.
    Wang JC
    Am J Hematol; 1988 Apr; 27(4):235-41. PubMed ID: 3258473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory role of human bone marrow fibroblasts in proliferation by granulocyte and macrophage colony-forming cells.
    Nagao T; Yamauchi K; Shimizu M; Noguchi K
    Exp Hematol; 1986 Aug; 14(7):696-701. PubMed ID: 3525204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone marrow histopathology and biological markers as specific clues to the differential diagnosis of essential thrombocythemia, polycythemia vera and prefibrotic or fibrotic agnogenic myeloid metaplasia.
    Michiels JJ
    Hematol J; 2004; 5(2):93-102. PubMed ID: 15048058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An in vitro study of basophil production in chronic myeloproliferative disorders.
    Piacibello W; Camussi G; Aglietta M
    Exp Hematol; 1984 Nov; 12(10):759-62. PubMed ID: 6334609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased circulating CSF-1 (M-CSF) in myeloproliferative disease: association with myeloid metaplasia and peripheral bone marrow extension.
    Gilbert HS; Praloran V; Stanley ER
    Blood; 1989 Sep; 74(4):1231-4. PubMed ID: 2669997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased fibroblast colony stimulating activity (F-CSA) in serum of myeloproliferative disorders.
    Han ZC; Briere J; Parent D; Abgrall JF; Sensebe L
    J Biol Regul Homeost Agents; 1988; 2(3):119-24. PubMed ID: 3267102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytogenetic studies of bone marrow fibroblasts cultured from patients with myelofibrosis and myeloid metaplasia.
    Wang JC; Lang HD; Lichter S; Weinstein M; Benn P
    Br J Haematol; 1992 Feb; 80(2):184-8. PubMed ID: 1550774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agnogenic myeloid metaplasia (AMM)--correlation of bone marrow lesions with laboratory data: a longitudinal clinicopathological study on 114 patients.
    Thiele J; Zankovich R; Steinberg T; Fischer R; Diehl V
    Hematol Oncol; 1989; 7(5):327-43. PubMed ID: 2767619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clonal analysis of agnogenic myeloid metaplasia.
    Kreipe H; Jaquet K; Felgner J; Parwaresch MR
    Leuk Lymphoma; 1992 Dec; 8(6):459-64. PubMed ID: 1363649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis.
    Vener C; Fracchiolla NS; Gianelli U; Calori R; Radaelli F; Iurlo A; Caberlon S; Gerli G; Boiocchi L; Deliliers GL
    Blood; 2008 Feb; 111(4):1862-5. PubMed ID: 18029552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of bone marrow fibrosis and subsequent development of polycythemia in patients with myeloproliferative disorders.
    Talarico L; Wolf BC; Kumar A; Weintraub LR
    Am J Hematol; 1989 Apr; 30(4):248-53. PubMed ID: 2929585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary (essential) thrombocythemia versus initial (hyperplastic) stages of agnogenic myeloid metaplasia with thrombocytosis--a critical evaluation of clinical and histomorphological data.
    Thiele J; Zankovich R; Steinberg T; Kremer B; Fischer R; Diehl V
    Acta Haematol; 1989; 81(4):192-202. PubMed ID: 2474228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative analysis of growth factor production in the mechanism of fibrosis in agnogenic myeloid metaplasia.
    Wang JC; Chang TH; Goldberg A; Novetsky AD; Lichter S; Lipton J
    Exp Hematol; 2006 Dec; 34(12):1617-23. PubMed ID: 17157157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progressive myelofibrosis in agnogenic myeloid metaplasia.
    Lohmann TP; Beckman EN
    Arch Pathol Lab Med; 1983 Nov; 107(11):593-4. PubMed ID: 6688716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
    Tefferi A
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased serum procollagen III aminoterminal peptide in myelofibrosis.
    Hochweiss S; Fruchtman S; Hahn EG; Gilbert H; Donovan PB; Johnson J; Goldberg JD; Berk PD
    Am J Hematol; 1983 Dec; 15(4):343-51. PubMed ID: 6650494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Properties of myelofibrosis-derived fibroblasts.
    Castro-Malaspina H; Jhanwar SC
    Prog Clin Biol Res; 1984; 154():307-22. PubMed ID: 6382300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Excess of blood group B in primary myelofibrosis.
    Jaff MS; O'Briain DS
    Vox Sang; 1987; 52(3):250-3. PubMed ID: 3111093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
    Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
    Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A preliminary study on humoral control of granulopoiesis in primary myelofibrosis and chronic granulocytic leukaemia.
    Brunelli MA; Bagnara GP; Astaldi G; Carnevali C; Topuz U; Rizzoli C
    Boll Ist Sieroter Milan; 1976; 55(5):431-5. PubMed ID: 1071009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.